Objectives: To identify demographic and clinical variables that relate to the postnatal increase in intestinal blood flow velocity in preterm infants.
Introduction
The superior mesenteric artery (SMA) is the major source of blood for the small intestine and to a portion of the large intestine. After birth, SMA blood flow velocity (SMA BFV) increases to support the dramatic increase in intestinal growth and oxygen uptake that occurs during the first few postnatal weeks. 1 There is increasing evidence that the rate of increase in SMA BFV may have clinical significance. Greater increases in postnatal SMA BFV during the first week of life in preterm infants are reportedly associated with less intestinal dysmotility, 2 and with better tolerance to enteral feedings. 3, 4 Intestinal blood flow is regulated by numerous factors including cardiovascular status, neural control, humoral substances and local control. 5, 6 Extrinsic factors that can affect splanchnic blood flow in preterm infants include the type and volume of enteral nutrition given, 3, [7] [8] [9] [10] and various pharmacologic agents, including indomethacin 11, 12 and caffeine. 13, 14 Although factors that can affect intestinal blood flow have been identified, little is known about factors that may affect the rate at which SMA BFV increases in newborn preterm infants. The objective of the present study was to identify demographic and clinical variables that relate to the postnatal increase in SMA BFV in low birth weight (LBW) preterm infants.
Subjects and methods

Study design
In this descriptive, prospective study, fasting or preprandial SMA BFV was measured once each day for the first 5 days of life. The relationship between SMA BFV and the following variables was measured: birth weight, gestational age, volume of feedings given, the number of days to reach full feeding volumes (150 ml/kg/day), type of feeding given, continuous positive airway pressure (CPAP) administration, hyperalimentation (HAL) administration and caffeine administration. CPAP, HAL and caffeine were investigated as they are the most commonly administered treatments in the population studied. For infants who were being fed enterally, measurements were made at least 3 h after a feeding was given.
Mean arterial pressure was recorded at the time SMA BFV measurements were made. This study was approved by the University of South Florida Institutional Review Board for the Protection of Human Subjects. Informed consent was obtained from a parent or guardian of each enrolled subject.
Subjects
Infants admitted to the neonatal intensive care unit (NICU) at Tampa General Hospital were eligible for enrollment. Inclusion criteria were birth weight <2500 g, gestational age <34 weeks and birth weight appropriate for gestational age. Exclusion criteria were the presence of major congenital anomalies, clinical evidence of significant cardiac abnormalities (including patent ductus arteriosus (PDA)), the administration of vasoactive drugs other than caffeine or a diagnosis of anemia (venous hemoglobin (Hgb) <10 g/dl) or polycythemia (venous Hgb >22 g/dl). Infants with umbilical artery catheters and infants who were intubated before day of life 5 were also excluded.
Clinical care
All infants were treated according to standard clinical care guidelines for the NICU. Starting on day 1 or 2 of life, infants with no contraindications to enteral feeding were given minimal enteral feedings (<20 ml/kg/day) that were advanced at 15 to 20 ml/kg/ day as tolerated. Feedings were given as boluses every 3 h, and included 24 kcal/oz preterm formula, or unfortified human milk. Nasal CPAP was applied to preterm neonates with signs of respiratory distress, HAL was administered starting on day 1 or 2 of life to maintain fluid and nutrient requirements, and caffeine was administered to infants with symptoms of apnea of prematurity.
Doppler ultrasound studies SMA BFV was measured using pulsed Doppler ultrasound (Acuson Sequoia C512, Mountainview, CA) and a 10.0 MHz transducer. The sampling volume of the pulsed Doppler was placed 3 mm distal to the origin of the SMA using a real-time two-dimensional image from a longitudinal abdominal approach. When five stable consecutive waveforms were obtained, the curve was traced and the mean peak systolic flow velocity (PSV), the time-averaged mean flow velocity (TAMV) and the mean end diastolic flow velocity (EDV) were recorded. The resistance index ((PSV-EDV)/PSV) and relative vascular resistance values (mean arterial pressure/TAMV) were calculated. All measurements were performed by one of two ultrasound technicians.
Statistical analyses
A mixed-effects linear model was used to describe the relationship between PSV, TAMV and the following variables: birth weight, gestational age, number of days required to reach full enteral feeding volumes (150 ml/kg/day), type of enteral feeding given during the 5-day study (formula or human milk), total volume of enteral feeding given during the 5-day study (ml/kg) and the administration of CPAP, HAL or caffeine during the 5-day study. To examine the treatment effects of CPAP, HAL and caffeine administration, infants who received these treatments were dichotomized post hoc into groups who were administered the treatments for <3 days, or for X3 days during the 5-day study. An additional mixed-effects linear model that included day of life, birth weight and gestational age as co-variates was used to describe the relationship between the daily change in PSV and TAMV, and CPAP and HAL administration.
Pearson's correlation was used to measure the relationship between the volume of enteral feeding given (ml/kg), and TAMV and PSV each day. Repeated measures analysis was used to measure the change in blood pressure, resistance index and relative vascular resistance from day 1 to 5. P-values less than 0.05 were considered statistically significant.
S-Plus, version 6.2 (Insightful Corp., Seattle, WA) and SPSS, version 11.5 (SPSS Corp., Chicago, IL) were used for statistical analyses. Values are reported as the mean±s.e.m., unless otherwise indicated.
Results
Twenty-seven infants were enrolled. After enrollment, one infant required treatment with indomethacin for a PDA, and one infant was intubated; data for these two infants were not included in the analyses. The mean birth weight and gestational age of the remaining 25 infants were 1740±68 g and 31.8±0.4 weeks, respectively (Table 1) . Enteral feedings began on day 1 for 11 of 25 infants; by day 5, all infants were being fed enterally. The mean (95% confidence interval (CI)) volume of formula or human milk administered to infants on study days 1 through 5 was 9 (2,15), 33 (18, 48) , 60 (38, 81), 71 (44, 97) and 82 (56, 107) ml/kg/day, respectively. Infants reached full feeding volumes at a mean age of 9.7 days (95% CI 7.7, 11.7). Eighty-eight percent (22/25) of infants were fed formula, 24% (6/25) were administered CPAP for X3 days, 60% (15/25) were administered HAL for X3 days and 12% (3/25) were administered caffeine for X3 days (Table 1) . Over 50% of the infants received treatment with antibiotics for X2 days, and one infant received azidothymidine for 2 days. Analyses on the relationship between SMA BFV and type of feed given and caffeine administration are not reported, as only three of 25 infants received human milk and only three of 25 infants were administered caffeine.
Doppler studies were completed for all 25 infants on each of the 5 study days.
The mixed-effects linear model identified HAL (P ¼ 0.037) as the only variable that was significantly related to the daily change in PSV; the relationship between the daily change in PSV and CPAP was marginally significant (P ¼ 0.057). CPAP (P ¼ 0.019), HAL (P ¼ 0.013) and the total volume of formula or human milk given during the 5-day study (P ¼ 0.018) were significantly related to the daily change in TAMV. The age at which enteral feedings were initiated and the total volume fed during the 5-day study period were 1.9±0.1 versus 1.2±0.1 days (P<0.001), and 100±10 and 458±15 ml/kg (P<0.001) for infants who received HAL for X3 days and for <3 days, respectively. The age at which enteral feedings were initiated and the total volume fed during the 5-day study period were 1.8±0.2 versus 1.5±0.2 days (P ¼ 0.20), and 66±16 and 300±20 ml/kg (P<0.001) for infants who received CPAP for X3 days and for <3 days, respectively.
For the entire cohort, there was a mean increase of 4.4±0.1 cm/ s/day for PSV (P<0.001) (Figure 1) , and a mean increase of 0.51±0.02 cm/s/day for TAMV (P ¼ 0.005) (Figure 2 ). The subgroup of infants who were administered CPAP for X3 days had an attenuated increase in TAMV (P ¼ 0.023) and PSV (P ¼ 0.058), even after adjustment for birth weight and gestational age ( Table 2 ). The subgroup of infants who were administered HAL for X3 days also had an attenuated increase in TAMV (P ¼ 0.006) and PSV (P ¼ 0.007), even after adjustment for birth weight and gestational age (Table 2 ). There was a significant correlation between mean TAMV and volume of enteral feedings given on day 2 (r ¼ 0.528, P ¼ 0.007) and day 4 (r ¼ 0.495, P ¼ 0.012), and a significant correlation between mean PSV and volume of enteral feedings given on day 2 (r ¼ 0.469, P ¼ 0.018).
Mean arterial pressure increased significantly from day 1 to days 2-5 (39.6±1.5, 46.0±1.9, 46.6±1.6, 45.9±1.6 and 45.8±1.1 mm Hg, respectively; P<0.005). There was no significant change in the resistance index from day 1 to 5 (0.79±0.01, 0.76±0.02, 
Discussion
Low birth weight preterm infants in our study had significant increases in fasting or preprandial TAMV and PSV from postnatal Intestinal blood flow in preterm infants T Havranek et al day 1 to 5. The increase in these measures was attenuated in infants who were administered CPAP or HAL for X3 days; to our knowledge, this is the first report suggesting that these treatments may relate to intestinal blood flow in preterm infants. As infants administered these CPAP or HAL generally have lower birth weights and gestational ages, we used a statistical model that controlled for the effect of these variables. The attenuating effects of CPAP and HAL on SMA BFV remained significant after controlling for birth weight and gestational age.
Other investigators have described postnatal increases in preprandial SMA BFV in preterm infants. 9, 10, [15] [16] [17] Most of the studies included fewer than 25 infants. Several investigators included ventilated infants; however, the effects of ventilation on SMA BFV were not reported. None of the previous studies indicated whether infants were administered HAL. Physiologic factors that are reported to play a role in the postnatal increase in SMA BFV include increasing blood pressure, decreasing intestinal vascular resistance, increasing stroke volume and spontaneous closure of the ductus arteriosus. 9, 10, 15, 16, 18 In our study, mean arterial pressure increased significantly from day 1 to 5, whereas intestinal vascular resistance did not change significantly.
CPAP is used increasingly for the treatment of respiratory distress in premature neonates. CPAP versus intubation/mechanical ventilation is associated with decreased incidences of bronchopulmonary dysplasia and sepsis, and with a trend toward decreased rates of retinopathy of prematurity and intraventricular hemorrhage. [19] [20] [21] CPAP, however, may contribute to the development of benign gaseous bowel distension in neonates (CPAP belly syndrome), 22 and it may be associated with an increased rate of necrotizing enterocolitis. 19, 20 It is not clear if the attenuated SMA BFV was owing to CPAP-related decreases in cardiac output, nor if bowel-related concerns with CPAP relate to our finding of attenuated increases in postnatal SMA BFV in infants on CPAP. However, other investigators have reported that attenuated increases in postnatal SMA BFV are associated with intestinal dysmotility, 2 and with feeding intolerance. 3, 4 Ongoing studies in our NICU are designed to further elucidate the relationship between CPAP, postnatal SMA BFV and clinical outcomes.
The attenuated SMA BFV in infants who received HAL for X3 days likely relates, at least in part, to delays in the introduction of enteral feedings and to the lower feeding volumes administered. Whereas enteral feeding relates to increases in postprandial SMA BFV in preterm infants, 4, [7] [8] [9] [10] 16 the relationship between enteral feeding and preprandial or fasting SMA BFV is unclear. Maruyama et al. 3 reported that enteral feeding volumes correlated with TAMV on just 3 of 6 postnatal days, we found that enteral feeding volumes correlated with SMA BFV on just 2 of 5 postnatal days and Yanowitz et al. 10 found no association between the initiation of enteral feeding and SMA BFV. An effect of HAL on intestinal function is suggested by the finding of Oste et al. 23 that parenterally fed preterm piglets had reduced trophic responses to enteral feedings, and fewer enteric nerves whose transmitter function depends on nitric oxide (NO) production. NO plays a major role in the regulation of SMA BFV. In piglets, the rates of constitutive and stimulated production of NO by the endothelial cell isoform of NO synthase are greatest in the early neonatal period. The role of constitutive NO production in setting basal intestinal vascular resistance is also greater in newborn piglets. 1, 24 It is unclear, however, whether these factors relate to our findings of lower SMA BFV in parenterally fed infants. Studies are also needed to determine if HAL has effects on SMA BFV and intestinal maturation that are independent of enteral feeding volumes.
A limitation of our study is the heterogeneity of the subject population and the potential effects of confounding variables on SMA BFV. For example, infants on CPAP and HAL usually have lower birth weights and gestational ages, and they usually receive lower volumes of enteral feedings. Although we controlled for the effects of birth weight and gestational age, and we found little correlation between enteral feeding volume and SMA BFV, a crossover study design would provide a more valid assessment of treatment effects on SMA BFV. An additional limitation of our study is the potential inclusion of infants who may have had nonsymptomatic PDA. Because splanchnic circulation is disturbed in infants with PDAs, 12, 25 this condition was an exclusion criteria for the study. However, the mean gestational age of infants was over 31 weeks, and many were not screened for the presence of PDAs. Ongoing SMA BFV studies include echocardiographic evaluation of PDAs and measurement of cardiac output, and include smaller, more critically ill infants.
In summary, our data support the findings of other investigators who reported that SMA BFV increases significantly in preterm LBW infants during the first week of life. In our study, the postnatal increase was attenuated in infants administered CPAP or HAL. Ongoing studies are designed to further clarify the relationship between SMA BFV and these and other treatments, and the clinical implications of attenuated increases in postnatal SMA BFV in preterm neonates.
